1   **Supplemental Table 1: Factors associated with odds of supplement/CAM use by country in the ASPREE**

2   **cohort**

Variables	Australia (n=13,455)		United States (n=1,683)	
	OR (95%CI)	p	OR (95%CI)	p
Age (*per year*)	0.99 (0.98-1.00)	0.007	0.99 (0.96-1.01)	0.183
Sex(*ref male)*	2.17 (2.01-2.34)	<0.001	2.15 (1.67-2.79)	<0.001
Education (*ref ≤ 12y education*)	1.20 (1.11-1.29)	<0.001	1.29 (0.98-1.70)	0.067
Living situation (*ref living alone*)	0.87 (0.81-0.94)	<0.001	0.86 (0.68-1.08)	0.196
Polypharmacy	1.24 (1.14-1.36)	<0.001	1.04 (0.78-1.38)	0.806
Diabetes	0.85 (0.77-0.95)	0.003	0.71 (0.52-0.96)	0.028
Frailty	1.06 (1.00-1.13)	0.034	1.13 (0.94-1.37)	0.194
Development of MACE in-trial [1]	0.71 (0.57-0.89)	0.002	0.71 (0.37-1.34)	0.285

3

4   Multivariate regression analysis stratified by sex. Values given as adjusted Odds Ratios (95% CI)

5   [1] MACE: major adverse cardiovascular events including nonfatal myocardial infarction (MI) and fatal or nonfatal ischemic
6   stroke.

7

8

9